Patents Assigned to RQX PHARMACEUTICALS, INC.
-
Patent number: 11072635Abstract: Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of bacterial type 1 signal peptidase (SpsB), an essential protein in bacteria. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.Type: GrantFiled: November 21, 2016Date of Patent: July 27, 2021Assignees: RQX Pharmaceuticals, Inc., Genentech, Inc.Inventors: Yongsheng Chen, Peter Andrew Smith, Tucker Curran Roberts, Robert I. Higuchi, Prasuna Paraselli, Michael F. T. Koehler, Jacob Bradley Schwarz, James John Crawford, Cuong Q. Ly, Huiyong Hu, Zhiyong Yu
-
Patent number: 10501493Abstract: Provided herein are analogs of the natural product arylomycin for the treatment of microbial infections. In some embodiments, the compounds described herein have broad spectrum bioactivity. The compounds provided herein can in other embodiments overcome the resistance conferred by single amino acid mutations at defined positions of bacterial Signal Peptidases (SPases) and in other embodiments provide for a broader spectrum of antibiotic bioactivity compared to the natural product. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.Type: GrantFiled: November 21, 2016Date of Patent: December 10, 2019Assignee: RQX PHARMACEUTICALS, INC.Inventors: Tucker Curran Roberts, Peter Andrew Smith, David Campbell, Sergio G. Duron, Robert I. Higuchi
-
Patent number: 10392422Abstract: Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of bacterial type 1 signal peptidase (SpsB), an essential protein in bacteria. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.Type: GrantFiled: May 19, 2015Date of Patent: August 27, 2019Assignees: RQX PHARMACEUTICALS, INC., GENENTECH, INC.Inventors: Tucker Curran Roberts, Peter Andrew Smith, Robert I. Higuchi, Prasuna Paraselli, Philippe Bergeron, Michael F. T. Koehler, Huiyong Hu, Jacob Bradley Schwarz, Cuong Ly, James John Crawford
-
Patent number: 10351595Abstract: Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of bacterial type 1 signal peptidase (SpsB), an essential protein in bacteria. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.Type: GrantFiled: May 19, 2015Date of Patent: July 16, 2019Assignees: RQX PHARMACEUTICALS, INC., GENENTECH, INC.Inventors: Tucker Curran Roberts, Peter Andrew Smith, Robert I. Higuchi, Prasuna Paraselli, Philippe Bergeron, Michael F. T. Koehler, Huiyong Hu, Jacob Bradley Schwarz, Cuong Ly, James John Crawford
-
Patent number: 9708368Abstract: Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. The compounds provided herein can in other embodiments overcome the resistance conferred by single amino acid mutations at defined positions of bacterial Signal Peptidases (SPases) and in other embodiments provide for a broad spectrum of antibiotic bioactivity. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.Type: GrantFiled: February 25, 2015Date of Patent: July 18, 2017Assignee: RQX PHARMACEUTICALS, INC.Inventors: Robert I. Higuchi, Tucker Curran Roberts, Peter Andrew Smith, David Campbell, Prasuna Paraselli
-
Publication number: 20170088582Abstract: Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of bacterial type 1 signal peptidase (SpsB), an essential protein in bacteria. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.Type: ApplicationFiled: May 19, 2015Publication date: March 30, 2017Applicants: RQX PHARMACEUTICALS, INC., GENENTECH, INC.Inventors: Tucker Curran ROBERTS, Peter Andrew SMITH, Robert I. HIGUCHI, Prasuna PARASELLI, Philippe BERGERON, Michael F.T. KOEHLER, Huiyong HU, Jacob Bradley SCHWARZ, Cuong LY, James CRAWFORD
-
Patent number: 9309285Abstract: Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of bacterial type 1 signal peptidase (SpsB), an essential protein in bacteria. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.Type: GrantFiled: November 21, 2013Date of Patent: April 12, 2016Assignee: RQX PHARMACEUTICALS, INC.Inventors: Tucker Curran Roberts, Peter Andrew Smith, Robert I. Higuchi, David Campbell, Prasuna Paraselli
-
Patent number: 8999922Abstract: Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. The compounds provided herein can in other embodiments overcome the resistance conferred by single amino acid mutations at defined positions of bacterial Signal Peptidases (SPases) and in other embodiments provide for a broad spectrum of antibiotic bioactivity. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.Type: GrantFiled: February 15, 2013Date of Patent: April 7, 2015Assignee: RQX Pharmaceuticals, Inc.Inventors: Robert I. Higuchi, Tucker Curran Roberts, Peter Andrew Smith, David Campbell, Prasuna Paraselli
-
Publication number: 20140249073Abstract: Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. The compounds provided herein can in other embodiments overcome the resistance conferred by single amino acid mutations at defined positions of bacterial Signal Peptidases (SPases) and in other embodiments provide for a broader spectrum of antibiotic bioactivity compared to the natural product. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.Type: ApplicationFiled: May 25, 2012Publication date: September 4, 2014Applicant: RQX PHARMACEUTICALS, INCInventors: Tucker Curran Roberts, Peter Andrew Smith, David Campbell, Sergio G. DurĂ³n, Robert I. Higuchi
-
Publication number: 20140142029Abstract: Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of bacterial type 1 signal peptidase (SpsB), an essential protein in bacteria. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.Type: ApplicationFiled: November 21, 2013Publication date: May 22, 2014Applicant: RQx Pharmaceuticals, Inc.Inventors: Tucker Curran ROBERTS, Peter Andrew SMITH, Robert I. HIGUCHI, David CAMPBELL, Prasuna PARASELLI
-
Publication number: 20130217619Abstract: Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. The compounds provided herein can in other embodiments overcome the resistance conferred by single amino acid mutations at defined positions of bacterial Signal Peptidases (SPases) and in other embodiments provide for a broad spectrum of antibiotic bioactivity. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.Type: ApplicationFiled: February 15, 2013Publication date: August 22, 2013Applicant: RQX PHARMACEUTICALS, INC.Inventor: RQX Pharmaceuticals, Inc.